stockportfolio.pro
MRNA vs RVMD: Which Stock Is the Better Buy?
Moderna, Inc. and Revolution Medicines, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — MRNA vs RVMD, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Moderna, Inc. (MRNA) | Revolution Medicines, Inc. (RVMD) | |
|---|---|---|
| Market cap | $31.6B | $31.3B |
| Revenue (latest FY) | $1.94B | $0 |
| Net income (latest FY) | $-2.82B | $-1.13B |
| Revenue growth (5y CAGR) | 19.3% | — |
| Net margin | -145.2% | — |
| Return on equity | -32.6% | -69.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 0 |
| Positive free cash flow | No | No |
See the full MRNA vs RVMD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open MRNA's full financials → Open RVMD's full financials →More comparisons
Frequently asked questions
Which is bigger, MRNA or RVMD?
Moderna, Inc. is larger by market capitalization — $31.6B versus $31.3B.
Which grows faster, MRNA or RVMD?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
MRNA fundamentals → · RVMD fundamentals → · All 1,500+ companies → · Free screener →